Annals of Hematology

, Volume 91, Issue 8, pp 1221–1233

Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes

Authors

  • Felicitas Thol
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Haiyang Yun
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Ann-Kathrin Sonntag
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Frederik Damm
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Eva M. Weissinger
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Jürgen Krauter
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Katharina Wagner
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Michael Morgan
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Martin Wichmann
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
  • Gudrun Göhring
    • Institute of Cell and Molecular PathologyHannover Medical School
  • Gesine Bug
    • Department of Internal Medicine IIIUniversity of Frankfurt
  • Oliver Ottmann
    • Department of Internal Medicine IIIUniversity of Frankfurt
  • Wolf-Karsten Hofmann
    • Department of Hematology and OncologyUniversity Hospital Mannheim
  • Axel Schambach
    • Department of Experimental HematologyHannover Medical School
  • Brigitte Schlegelberger
    • Institute of Cell and Molecular PathologyHannover Medical School
  • Torsten Haferlach
    • MLL, Munich Leukemia Laboratory
  • David Bowen
    • St James’s Institute of OncologyLeeds Teaching Hospitals
  • Ken Mills
    • Centre for Cancer Research and Cell BiologyQueen’s University Belfast
  • Arnold Ganser
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
    • Department of Hematology, Hemostasis, Oncology, and Stem Cell TransplantationHannover Medical School
Original Article

DOI: 10.1007/s00277-012-1457-7

Cite this article as:
Thol, F., Yun, H., Sonntag, A. et al. Ann Hematol (2012) 91: 1221. doi:10.1007/s00277-012-1457-7

Abstract

Overexpression of MN1, ERG, BAALC, and EVI1 (MEBE) genes in cytogenetically normal acute myeloid leukemia (AML) patients is associated with poor prognosis, but their prognostic effect in patients with myelodysplastic syndromes (MDS) has not been studied systematically. Expression data of the four genes from 140 MDS patients were combined in an additive score, which was validated in an independent patient cohort of 110 MDS patients. A high MEBE score, defined as high expression of at least two of the four genes, predicted a significantly shorter overall survival (OS) (HR 2.29, 95 % CI 1.3–4.09, P = .005) and time to AML progression (HR 4.83, 95 % CI 2.01–11.57, P < .001) compared to a low MEBE score in multivariate analysis independent of karyotype, percentage of bone marrow blasts, transfusion dependence, ASXL1, and IDH1 mutation status. In a validation cohort of 110 MDS patients, a high MEBE score predicted shorter OS (HR 1.77; 95 % CI 1.04–3.0, P = .034) and time to AML progression (HR 3.0, 95 % CI 1.17–7.65, P = .022). A high MEBE expression score is an unfavorable prognostic marker in MDS and is associated with an increased risk for progression to AML. Expression of the MEBE genes is regulated by FLI1 and c-MYC, which are potential upstream targets of the MEBE signature.

Keywords

MDSPrognosisGene expressionScoreSplicing

Supplementary material

277_2012_1457_MOESM1_ESM.doc (102 kb)
Table S1Comparison of clinical and molecular characteristics of MDS patients with low or high MN1 expression. (DOC 102 kb)
277_2012_1457_MOESM2_ESM.doc (101 kb)
Table S2Comparison of clinical and molecular characteristics of MDS patients with low or high ERG expression. (DOC 101 kb)
277_2012_1457_MOESM3_ESM.doc (101 kb)
Table S3Comparison of clinical and molecular characteristics of MDS patients with low or high BAALC expression. (DOC 101 kb)
277_2012_1457_MOESM4_ESM.doc (102 kb)
Table S4Comparison of clinical and molecular characteristics of MDS patients with low or high EVI1 expression. (DOC 102 kb)
277_2012_1457_MOESM5_ESM.doc (44 kb)
Table S5Correlation between MN1, ERG, BAALC and EVI1 expression in MDS patients. (DOC 43 kb)
277_2012_1457_MOESM6_ESM.doc (126 kb)
Table S6List of gene sets enriched or depleted in MDS patients with high MEBE expression score. (DOC 126 kb)
277_2012_1457_MOESM7_ESM.doc (42 kb)
Table S7Primers used to quantify expression of mouse Mn1, Erg, Baalc, and Evi1. (DOC 42 kb)
277_2012_1457_MOESM8_ESM.doc (206 kb)
Supplemental Figure S1Prognostic impact of individual gene expression markers in MDS patients in the validation cohort. Kaplan-Meier curves for overall survival and time to AMLtransformation are shown. (A) Overall survival in MDS patients with low or high MN1 expression. (B) Time to AML transformation in MDS patients with low or high MN1 expression. (C) Overall survival in MDS patients with low or high ERG expression. (D) Time to AML transformation in MDS patients with low or high ERG expression. (E) Overall survival in MDS patients with low or high BAALC expression. (F) Time to AML transformation in MDS patients with low or high BAALC expression. (G) Overall survival in MDS patients with high EVI1 vs. low EVI1 expression (see Materials and Methods for definition of high vs. low expression). Time to AML transformation in MDS patients with high EVI1 vs. low EVI1 expression (see Materials and Methods for definition of high vs. low expression). (DOC 205 kb)
277_2012_1457_MOESM9_ESM.doc (124 kb)
Supplemental Figure S2Prognostic impact of the MEBE expression score in younger and older MDS patients. (A) Overall survival in MDS patients younger than 66 years of age with low or high MEBE score. (B) Time to AML transformation in MDS patients younger than 66 years of age with low or high MEBE score. (C) Overall survival in MDS patients 66 years of age or older with low or high MEBE score. Time to AML transformation in MDS patients 66 years of age or older with low) or high MEBE score. (DOC 124 kb)
277_2012_1457_MOESM10_ESM.doc (122 kb)
Supplemental Figure S3Prognostic impact of the MEBE expression score determined from bone marrow or peripheral blood in MDS patients. (A) Only bone marrow (BM) samples considered: Overall survival in MDS patients with low or high MEBE score. (B) Only bone marrow samples (BM) considered: Time to AML transformation in MDS patients with low or high MEBE score. (C) Only peripheral blood samples considered: Overall survival in MDS patients with low or high MEBE score. (D) Only peripheral blood samples considered: Time to AML transformation in MDS patients with low or high MEBE score (DOC 122 kb)
277_2012_1457_MOESM11_ESM.doc (70 kb)
Supplemental Figure S4Prognostic impact of the MEBE expression score in MDS patients with 10-19 percent bone marrow blasts. (A) Overall survival in MDS patients with low or high MEBE score in patients with 10-19 percent bone marrow blasts. (B) Time to AML transformation in MDS patients with low or high MEBE score in patients with 10-19 percent bone marrow blasts. (DOC 70 kb)
277_2012_1457_MOESM12_ESM.doc (142 kb)
Supplemental Figure S5Correlation of expression classes (high or low) of individual gene expression markers of the MEBE score. Each row represents one patient. Yellow, low expression or low MEBE score. Blue, high expression or high MEBE score. (DOC 142 kb)
277_2012_1457_MOESM13_ESM.doc (97 kb)
Supplemental Figure S6Effect of constitutive expression of Fli1 and c-Myc on expression levels of Mn1, Erg, Baalc, and Evi1 in mouse bone marrow cells. Fli1, c-Myc, or a control vector was stably expressed in mouse bone marrow cells. Transduced cells were sorted and harvested after 7 days, and cDNA was prepared for expression analysis. Abl was used as a housekeeping gene, and expression ratios of transgene expressing cells vs. control vector-transduced cells are shown (n=3, mean ± SD). Expression of Baalc could be detected by nested PCR only. (DOC 97 kb)

Copyright information

© Springer-Verlag 2012